Opendata, web and dolomites

Obsidian SIGNED

Obsidian Anastomotic SafeGuard – A powerful and efficient tissue sealant method for reducing the anastomotic leak rate in colorectal surgery

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Obsidian project word cloud

Explore the words cloud of the Obsidian project. It provides you a very rough idea of what is the project "Obsidian" about.

approx    cancer    disease    colorectal    asia    42m    reduces    site    wound    commercialization    blood    eliminated    instrument    post    components    diseases    setting    market    intestinal    million    contains    healing    astonishing    97m    offers    revenue    vivostat    platelet    societal    tissue    sealing    faces    first    preparation    natural    thrombin    opportunity    ibd    300    selant    stump    full    procedure    obsidian    leaks    transmission    solution    resection    added    grant    solid    issue    2018    ends    biocompatibility    ibds    autologous    fibrin    sealant    19    surgery    minutes    significantly    p1    inflammatory    fast    treating    considering    grow    oceania    adding    bovine    time    reg    business    3rd    risk    prepation    anastomotic    needing    conduct    sme    79m    decrease    14    gastrointestinal    applicable    anastomosis    total    huge    patients    rate    rates    2b    leak    leveraging    stimulation    gluing    asg    profits    worldwide    24    bowel    completing    clinical   

Project "Obsidian" data sheet

The following table provides information about the project.

Coordinator
Vivostat A/S 

Organization address
address: BORUPVANG 2
city: ALLEROD
postcode: 3450
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Denmark [DK]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-12-01   to  2020-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    Vivostat A/S DK (ALLEROD) coordinator 50˙000.00

Map

 Project objective

Obsidian ASG® is the first – and only - autologous fibrin tissue sealant applicable for gastrointestinal anastomosis, that will significantly decrease the anastomotic leak rate, following gastrointestinal resection when treating Inflammatory Bowel Diseases (IBDs) or Colorectal Cancer. The current number of anastomotic leak rates is a large societal issue, as studies show rates as high as 19%. Considering that approx. 1.8 million new cases of colorectal cancer will occur worldwide in 2018 (being the 3rd most common cancer type), the number of leaks is astonishing – and this is only for colorectal cancer. Adding the number of IBD patients needing a resection, Obsidian ASG® faces a market potential of 0.79M patients just in Europe, Asia and Oceania every year. Leveraging on this market opportunity, Obsidian ASG® contains all the components needed for on-site prepation and application of an autologous platelet rich fibrin selant – a preparation that can be completed in less than 30 minutes. As the only product in the market, Obsidian ASG® offers 1) a long-term cost-effective procedure for gluing and sealing intestinal stump-ends; 2) A fast and natural stimulation of wound healing that significantly reduces the anastomotic leak rates; and 3) Full biocompatibility, eliminated risk of blood disease transmission and no thrombin or bovine components added to the blood or Obsidian ASG® solution at any time during the process. Yet, to reach market commercialization, we need to conduct a clinical study of Obsidian ASG® with 300 colorectal pre-surgery patients. The SME P1 grant will be crucial for completing the design of the clinical study as well as setting up key partnerships for the proposed clinical study (to be set up in a SME-2b Instrument Project). As such, the SME-Instrument represents a huge opportunity for Vivostat A/S, as we expect to grow a solid business case year 1-5 post-project, with a total revenue of €24.97M and profits of €14.42M.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "OBSIDIAN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "OBSIDIAN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

MealHero (2019)

Automated cooking for tasty and healthy meals in a convenient way

Read More  

AMBRPAY (2019)

Decentralized subscription payments with cryptocurrency

Read More  

GUARDIAN (2020)

Eco-friendly smart doors for non-residential building fire protection

Read More